Skip to main content
Press Release

OQC and Kvantify announce new InnovateUK project, CoaxChem, to develop novel quantum solution to batteries

Black background with white OQC logo.
PRESS RELEASE

OQC and Kvantify announce new InnovateUK project, CoaxChem, to develop novel quantum solution to batteries

SHARE ARTICLE

Discovering new components for batteries involves time-consuming and costly research and development. Typically, to boost efficiency, battery manufacturers use chemical computation to narrow down the best battery component candidates. However, most chemical computations currently used offer limited efficacy only and struggle to simulate complex systems with high precision due to the vastness of the problem space. Developing quantum software on quantum computers can tackle this challenge due to their immense potential for error reduction, performance optimisation and computational power, which can be exponentially scaled.

A strategic response to the challenges and opportunities with battery development and manufacturing, the international research and development collaboration will develop an innovative chemical model for battery chemistry, integrating OQC’s quantum hardware with Kvantify’s proprietary quantum chemistry platform, and co-optimising OQC’s hardware with Kvantify’s software to enhance performance and results. In addition, CoaxChem’s solution will be designed to enable future adoption with fault-tolerant quantum computers (FTQCs), once they become available.

CoaxChem is poised to solve a variety of complex problems in battery chemistry, such as battery oxidation and electrolyte degradation, enabling the creation of novel, cost-efficient and reliable battery components, while capitalising on emerging opportunities within the energy industry. The innovative platform developed in CoaxChem is built upon the best available quantum chemistry algorithms from Kvantify, which are designed with quantum hardware in mind, presenting unique capabilities to tackle intricate chemistry problems even with the challenges posed by NISQ devices. OQC’s quantum hardware guarantees a scalable, top-quality 3D superconducting qubit design which is unique in quantum computing, providing the right framework to co-design and integrate with Kvantify’s chemistry platform.

The development and deployment of a quantum chemistry platform which can be adapted to fault tolerant quantum computers constitutes a groundbreaking advancement not yet achieved. CoaxChem’s innovative approach positions the developed product as a pioneering solution in the quantum computing ecosystem, offering unique computational capabilities, unmatched by current market offerings, to aid in the R&D and manufacturing of novel batteries.

About OQC
OQC is a global leader in quantum computing-as-a-service, delivering enterprise-ready quantum solutions for its customers. As the first commercially available quantum computing company in the UK and Europe, OQC has continuously pushed technological boundaries—from launching the first quantum compute-as-a-service platform in Europe to deploying a quantum computer in a commercial data center with high-performance computing integration. By breaking down technical, financial, and geographical barriers, OQC empowers enterprises worldwide to harness the power of quantum computing for a competitive edge.

About Kvantify
Kvantify is a life science company based in Denmark that is working to accelerate discovery of new medicine for the good of patients. For that they are developing a novel physics-based end-to-end drug-discovery platform that is designed to outperform conventional classical computing solutions today, and ready to take advantage of quantum computers tomorrow. They offer Collaborative Drug Discovery Services that leverage their proprietary tools as well as other state-of-the-art methods. Specifically designed for pharma and biotech companies, their Drug Discovery Platform covers the computational steps from Hit-ID to Lead Optimisation, enabling customers to move from thousands to a handful of very high-quality compounds. Their ambition is to provide significantly better calculations than what is available today along the steps in the drug discovery process with the aim of increasing the success rate for identifying and bringing new medicine to market.